Kaken Pharmaceutical (4521) Stock Overview
Produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
4521 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Kaken Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,140.00 |
| 52 Week High | JP¥4,445.00 |
| 52 Week Low | JP¥3,540.00 |
| Beta | 0.15 |
| 1 Month Change | -1.66% |
| 3 Month Change | 0.49% |
| 1 Year Change | 2.83% |
| 3 Year Change | 11.89% |
| 5 Year Change | -6.02% |
| Change since IPO | 72.50% |
Recent News & Updates
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00
Dec 19
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00
Nov 29Recent updates
Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00
Dec 19Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥95.00
Nov 29We Think You Can Look Beyond Kaken Pharmaceutical's (TSE:4521) Lackluster Earnings
Nov 18We Think Kaken Pharmaceutical's (TSE:4521) Robust Earnings Are Conservative
May 19We Think Kaken Pharmaceutical (TSE:4521) Can Manage Its Debt With Ease
May 12There's Reason For Concern Over Kaken Pharmaceutical Co., Ltd.'s (TSE:4521) Price
Apr 15Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00
Mar 27Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00
Mar 13Kaken Pharmaceutical (TSE:4521) Has Affirmed Its Dividend Of ¥75.00
Feb 27Kaken Pharmaceutical (TSE:4521) Is Due To Pay A Dividend Of ¥75.00
Feb 10Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00
Jan 10Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00
Dec 20Kaken Pharmaceutical (TSE:4521) Will Pay A Dividend Of ¥75.00
Dec 02Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)
Aug 13Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00
Jul 26Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00
Jul 11Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00
Mar 04Shareholder Returns
| 4521 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -2.1% | -3.4% | 2.4% |
| 1Y | 2.8% | 33.4% | 47.7% |
Return vs Industry: 4521 underperformed the JP Pharmaceuticals industry which returned 33.4% over the past year.
Return vs Market: 4521 underperformed the JP Market which returned 47.7% over the past year.
Price Volatility
| 4521 volatility | |
|---|---|
| 4521 Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.4% |
Stable Share Price: 4521 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4521's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 1,126 | Hiroyuki Horiuchi | www.kaken.co.jp |
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle.
Kaken Pharmaceutical Co., Ltd. Fundamentals Summary
| 4521 fundamental statistics | |
|---|---|
| Market cap | JP¥156.77b |
| Earnings (TTM) | -JP¥3.83b |
| Revenue (TTM) | JP¥75.66b |
Is 4521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4521 income statement (TTM) | |
|---|---|
| Revenue | JP¥75.66b |
| Cost of Revenue | JP¥35.49b |
| Gross Profit | JP¥40.17b |
| Other Expenses | JP¥44.00b |
| Earnings | -JP¥3.83b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 13, 2026
| Earnings per share (EPS) | -101.19 |
| Gross Margin | 53.09% |
| Net Profit Margin | -5.06% |
| Debt/Equity Ratio | 2.6% |
How did 4521 perform over the long term?
See historical performance and comparisonDividends
Does 4521 pay a reliable dividends?
See 4521 dividend history and benchmarks| Kaken Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 30 2026 |
| Days until Ex dividend | 16 days |
| Days until Dividend pay date | 76 days |
Does 4521 pay a reliable dividends?
See 4521 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 00:56 |
| End of Day Share Price | 2026/04/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kaken Pharmaceutical Co., Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |
| Junya Yamazaki | Jefferies LLC |
| Toshiyuki Iwata | Mizuho Securities Co., Ltd. |